Why the study?
Does warfarin use reduce thromboembolic events in patients with nonrheumatic atrial fibrillation at low or intermediate risk?
Does warfarin use reduce thromboembolic events in patients with nonrheumatic atrial fibrillation at low or intermediate risk?
In patients with nonrheumatic atrial fibrillation, lack of warfarin use is associated with a higher risk of thromboembolic events in intermediate-risk (CHADS2=1) patients, but warfarin does not significantly reduce events in low-risk (CHADS2=0) patients.
No takes yet. Share an insight, caveat, or question.
Supports considering warfarin in intermediate-risk nonrheumatic AF; leaves open randomized confirmation for low-risk patients.
Chae et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: